Silence Therapeutics
SLN
28 hedge funds and large institutions have $188M invested in Silence Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
84% more capital invested
Capital invested by funds: $102M → $188M (+$85.8M)
0.46% more ownership
Funds ownership: 17.84% → 18.29% (+0.46%)
3% less funds holding
Funds holding: 29 → 28 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$5.9M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.74M |
| 3 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$211K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$57.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.06M |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$928K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$537K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$477K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$461K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| $1.75K | +$1.31K | +178 | New |
|
|
SPIA
27
Steward Partners Investment Advisory
New York
| $982 | – | – | – |
|
28
RhumbLine Advisers
Boston,
Massachusetts
| $49 | +$37 | +5 | New |
|
|
29
Point72 Asset Management
Stamford,
Connecticut
| – | -$477K | -86,700 | Closed |
|
30
Axa
Paris,
France
| – | -$322K | -58,624 | Closed |
|
31
Millennium Management
New York
| – | -$126K | -22,832 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$4.4K | -800 | Closed |
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | -$27 | -5 | Closed |
|
SLN Hedge Fund Activity: Q3 2023 in Review
28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2023, worth a combined $188M — up 84% from $102M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SLN and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Artal Group, adding an estimated $5.9M. The largest seller was Goldman Sachs, cutting an estimated $1.06M.
- 28 institutional investors held Silence Therapeutics (SLN) as of Q3 2023, down from 29 in Q2 2023.
- Funds reported $188M of Silence Therapeutics stock for Q3 2023, up 84% quarter-over-quarter.
- 4 funds opened new Silence Therapeutics positions in Q3 2023 and 5 closed out, a net change of -1 holder.
- The largest Silence Therapeutics buyer in Q3 2023 was Artal Group, an estimated $5.9M added.
- The largest Silence Therapeutics seller in Q3 2023 was Goldman Sachs, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2023.